Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2026)

C4 Therapeutics has reported Non-Current Deffered Revenue over the past 8 years, most recently at $15.4 million for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue fell 38.53% year-over-year to $15.4 million; the TTM value through Mar 2026 reached $15.4 million, down 38.53%, while the annual FY2025 figure was $15.8 million, 44.33% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2026 was $15.4 million at C4 Therapeutics, down from $15.8 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $28.6 million in Q3 2024 and troughed at $15.4 million in Q1 2026.
  • A 5-year average of $20.3 million and a median of $19.6 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: tumbled 62.62% in 2022 and later skyrocketed 45.99% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $16.9 million in 2022, then grew by 29.12% to $21.8 million in 2023, then surged by 30.45% to $28.5 million in 2024, then plummeted by 44.33% to $15.8 million in 2025, then decreased by 2.53% to $15.4 million in 2026.
  • Business Quant data shows Non-Current Deffered Revenue for CCCC at $15.4 million in Q1 2026, $15.8 million in Q4 2025, and $19.9 million in Q3 2025.